GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » Debt-to-EBITDA

Vivani Medical (Vivani Medical) Debt-to-EBITDA : -0.83 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vivani Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.43 Mil. Vivani Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $18.94 Mil. Vivani Medical's annualized EBITDA for the quarter that ended in Mar. 2024 was $-24.51 Mil. Vivani Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.83.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vivani Medical's Debt-to-EBITDA or its related term are showing as below:

VANI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.78   Med: -0.21   Max: -0.05
Current: -0.78

During the past 4 years, the highest Debt-to-EBITDA Ratio of Vivani Medical was -0.05. The lowest was -0.78. And the median was -0.21.

VANI's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs VANI: -0.78

Vivani Medical Debt-to-EBITDA Historical Data

The historical data trend for Vivani Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical Debt-to-EBITDA Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.28 -0.14 -0.05 -0.78

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.76 -0.74 -0.85 -0.83

Competitive Comparison of Vivani Medical's Debt-to-EBITDA

For the Biotechnology subindustry, Vivani Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivani Medical's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vivani Medical's Debt-to-EBITDA falls into.



Vivani Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vivani Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.383 + 19.313) / -26.608
=-0.78

Vivani Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.434 + 18.94) / -24.512
=-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Vivani Medical  (NAS:VANI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vivani Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vivani Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical (Vivani Medical) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 280, Emeryville, CA, USA, 94608
Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
Executives
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342